Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sogang University R&Db Foundation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves a distinct examiner and a distinct art unit. With a distinct art unit involved, the foundation's current patenting activity is localized within the patent office's organizational structure. This focus indicates that the foundation is currently pursuing protection for a specific set of biological or pharmaceutical innovations rather than a broad array of diverse technologies.
MADELINE E BRAUN is the busiest examiner for the foundation, currently handling 1 pending office action. This examiner manages the full extent of the foundation's active office actions. Since there is a pending office action, the foundation's administrative burden at the patent office is currently low. The outcome of this action will be significant for the foundation's intellectual property position in the Biotechnology & Pharmaceuticals sector, as it represents the entirety of their current pending workload. Practitioners should prepare for detailed technical discussions given the specialized nature of this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289872 | COMPOUND COMPRISING PYRROLIDINE AS LINKER, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BRAUN, MADELINE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289872 | COMPOUND COMPRISING PYRROLIDINE AS LINKER, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289872 | COMPOUND COMPRISING PYRROLIDINE AS LINKER, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BRAUN, MADELINE E | 1624 | §102§112 | Final Rejection | — | Pending | Nov 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSogang University R&Db Foundation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Madeline E Braun has the most, with 1 of Sogang University R&Db Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
